- Home
- RGC vs HSIC Comparison
RGC vs HSIC Comparison
Compare RGC & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | HSIC |
|---|---|---|
| Founded | 2014 | 1932 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.8B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RGC | HSIC |
|---|---|---|
| Price | $20.92 | $76.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $76.50 |
| AVG Volume (30 Days) | 328.1K | ★ 1.1M |
| Earning Date | 10-24-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.70 |
| EPS | N/A | ★ 3.17 |
| Revenue | N/A | ★ $12,938,000,000.00 |
| Revenue This Year | N/A | $5.35 |
| Revenue Next Year | N/A | $3.34 |
| P/E Ratio | ★ N/A | $23.85 |
| Revenue Growth | N/A | ★ 3.51 |
| 52 Week Low | $0.09 | $60.56 |
| 52 Week High | $83.60 | $82.49 |
Technical Indicators
Market Signals| Indicator | RGC | HSIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 60.03 |
| Support Level | $19.80 | $75.65 |
| Resistance Level | $25.50 | $76.95 |
| Average True Range (ATR) | 2.71 | 1.10 |
| MACD | 0.13 | -0.29 |
| Stochastic Oscillator | 47.37 | 54.12 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.